期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CCR4与肿瘤的关系及其临床意义 被引量：2

Involvement of CCR4 in tumor and its clinical significance
下载PDF
导出
摘要 CCR4是CC趋化因子受体(CC chemokine receptor,CCR)家族中的一员,主要表达于多种淋巴细胞。其高亲和力配体为胸腺和活化调节的趋化因子(thymus and activation regulated chemokine,TARC/CCL17)及巨噬细胞衍生的趋化因子(macrophage-derived chemokine,MDC/CCL22/STCP-1)。CCR4主要通过CCR4+Treg细胞及CCR4+Th2细胞发挥免疫效应。CCR4的高表达与多种血液系统肿瘤以及恶性实体瘤的浸润和预后相关,其机制为Treg细胞表面的CCR4通过与其配体TARC、MDC的结合趋化Treg细胞,引起免疫逃逸,从而导致不良临床后果。多种恶性肿瘤转移模型的研究进一步揭示了CCR4与恶性肿瘤转移之间的关系。抗CCR4嵌合型单克隆抗体KM2760的研究已进入Ⅱ期临床试验阶段,阻断TARC/MDC-CCR4信号通路,有可能成为恶性肿瘤分子靶向治疗的新策略。 CCR4,a member of CCR（CC chemokine receptor） family,is expressed in many kinds of lymphocytes.Its high affinity ligands include thymus,activation regulated chemokine（TARC/CCL17） and macrophage-derived chemokine（MDC/CCL22/STCP-1）.CCR4 exerts its immune activities by CCR4＋Treg cells and CCR4＋Th2 cells.High expression of CCR4 is associated with infiltration and prognosis of many hematological and solid malignancies;the binding of CCR4 with its ligands TARC and MDC in Treg cells may be responsible for the chemotaxis of Treg cells,the resulting immune tolerance and worse clinical outcomes.The researches of malignant tumor metastatic models further revealed the relationship between CCR4 expression and metastasis of malignant solid tumors.The study of KW-0761,a defucosylated humanized anti-CCR4 antibody,has already been in the phase Ⅱ clinical trial.Therefore,blockage TARC/MDC-CCR4 signal pathway might be a novel therapy strategy for malignant tumors.
作者 顾筱莉 欧周罗 邵志敏
机构地区 复旦大学肿瘤医院乳腺癌研究所
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2010年第3期339-343,共5页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.30570695) 国家重大科学研究计划(No.2006CB910501)~~
关键词 CC趋化因子受体-4(CCR4) 胸腺和活化调节的趋化因子(TARC) 巨噬细胞衍生的趋化因子(MDC) 肿瘤 CC chemokine receptor-4（CCR4） thymus and activation regulated chemokine（TARC） macrophage-derived chemokine（MDC） neoplasms
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献34

  • 1Power CA, Meyer A, Nemeth K, Bacon KB, Hoogewerf AJ, Proudfoot AE, et al. Molecular-cloning and functional expression of a novel CC-chemokine receptor cDNA from a human basophilic cell-line [J]. J Biol Chem, 1995, 270 (33), 19495-19500.
  • 2Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q, et al. Chemokine-like factor I is a functional ligand for CC chemokine receptor4 (CCR4) [J]. LifeSci, 2006, 78(6) : 614-621.
  • 3lmai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4 [J]. J Biol Chem, 1998, 273(3) : 1764-1768.
  • 4Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer [ J ] . Cancer Sci, 2006, 97 ( 11 ) : 1139-1146.
  • 5Woo EY, Yeh H, Chu CS, Schleinger K, Carroll RG, Riley JL, et al. Regulator, T cells from lung cancer patients directly inhibit autologous T cell proliferation [ J]. J Immunol, 2002, 168 (9) : 4272 -4276.
  • 6Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, et al. Human CD25 ( + ) CD4 ( + ) T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells [ J]. J Exp Med, 2002, 196(10): 1335-1346.
  • 7Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4 ( + ) CD25 ( + ) regulatory T eells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative [ J ]. Eur J hnmunol, 2004, 34(2) : 336-344.
  • 8Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: Paradigm lost [ J]. Crit Rev Immunol, 1999, 19(2) : 155-172.
  • 9Ohshima K, Kanabe K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression : Analysis of prognosis [ J]. Int J Oncol, 2004, 25(3) : 605-613.
  • 10Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma [J]. Clin Cancer Res, 2004, 10(22) : 7529-7539.

同被引文献57

  • 1Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007, 110(6): 1713-1722.
  • 2Stover DG, Bierie B, Moses HL. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem, 2007, 101 (4): 851-861.
  • 3Mohla S. Tumor microenvironment. J Cell Biochem, 2007, 101 (4): 801-804.
  • 4Der-Petrossian M, Valencak J, Jonak C, et al. Dermal infiltrates of cutaneous T-cell lymphomas with epidermotropism but not other cutaneous lymphomas are abundant with langefin+ dendritic cells. J Eur Acad Dermatol Venereol, 2011, 25(8): 922-927.
  • 5Luftl M, Feng A, Lieha E, Schuler G.Dendritie cells and apoptosis in mycosis fungoides, Br J Dermatol. 2002,147 (6): 1171-1179.
  • 6Schwingshackl P, Obermoser G, Nguyen VA, et al. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and SSzary syndrome. Acta Derm Venereol, 2012, 92 (3): 269-275.
  • 7Ni X, Duvic M. Dendritic ceils and cutaneous T-cell lymphomas. G Ital Dermatol Venereol, 2011, 146(2): 103-113.
  • 8Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sezary syndrome. Lancet, 2008, 371(9616): 945-957.
  • 9Dobbeling U. Transcription factor profiling shows new ways towards new treatment options of cutaneous T cell lymphomas. Curr Drug Discov Technol, 2007, 4( 1 ): 24-30.
  • 10Yao X, Ahmadzadeh M, Lu YC, et al. Levels of peripheral CD4^+ FoxP3^+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood, 2012, 119(24): 5688-5696.

引证文献2

二级引证文献4

中国肿瘤生物治疗杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部